Pfizer Stock Price Today Per Share: Why the Yield is Looking Juicy But the Outlook is Kinda Messy

Honestly, if you've been looking at the Pfizer stock price today per share, you're probably feeling one of two things: either you're salivating over that massive dividend yield, or you're wondering how a company that basically saved the world a few years ago is currently trading at levels we haven't seen in a decade.

It's a weird spot to be in. As of the market close on Friday, January 16, 2026, Pfizer (PFE) settled at $25.65. That's down about 0.9% on the day, but the bigger story is the longer trend. We're looking at a 52-week range that’s topped out at $27.69 and bottomed near $20.92.

The Numbers You Actually Care About Today

Let's cut through the corporate jargon. Here is the raw data for where things stand right now:
The stock opened Friday at $25.89 and bounced around a bit before ending at $25.65. Volume was pretty high, with over 59 million shares changing hands. That tells us people are definitely trading this thing, but they aren't exactly rushing to buy it up.

The Price-to-Earnings (P/E) ratio is sitting around 14.9, which, compared to some of the high-flying tech stocks, makes it look dirt cheap. But there’s a reason it’s cheap. Investors are worried about the "patent cliff"—that scary moment when a drug company loses its exclusive rights to sell a blockbuster medicine.

That 6.7% Dividend Yield

For income investors, the dividend is the only reason to even look at PFE right now. The company just declared a $0.43 per share quarterly dividend. If you own the stock by the record date of January 23, 2026, you’ll get paid on March 6.
Basically, you're getting paid about 6.7% to 6.8% annually just to hold the stock. That's way better than a savings account, but only if the stock price doesn't keep sliding.

Why the Pfizer Stock Price Today Per Share Is Struggling

It’s not just one thing; it’s a "perfect storm" of headaches.
First, the COVID-19 cash cow is officially dead. Revenue from Comirnaty (the vaccine) and Paxlovid is expected to drop another $1.5 billion in 2026. Everyone who wanted a shot has had four, and the demand just isn't there anymore.

💡 You might also like: CITGO Lemont Refinery: What You Need to Know About the Illinois Energy Hub

Then you have the patent issues. Eliquis, the blood thinner they co-own with Bristol Myers Squibb, is heading toward generic competition. So are Ibrance and Xtandi. Management thinks these patent losses will shave another $1.5 billion off the top line this year.

The 2026 Guidance Shocker

In December 2025, Pfizer released its outlook for 2026, and it wasn't what Wall Street wanted to hear. They’re projecting revenue between $59.5 billion and $62.5 billion.
The midpoint of that is actually lower than what they did in 2025.
Even worse, they expect adjusted earnings per share (EPS) to land between $2.80 and $3.00. Last year, they were looking at $3.00 to $3.15. So, we're looking at a company that is technically shrinking for the moment.

Is There a Light at the End of the Tunnel?

It's not all doom and gloom. Pfizer is basically trying to buy its way out of this hole.
They spent a fortune acquiring Seagen to become a leader in oncology (cancer treatment). They also picked up Metsera recently to get into the obesity drug game. Everyone is obsessed with Wegovy and Zepbound right now, and Pfizer really needs a win in that space.

Watch the Pipeline

If you're holding PFE, you're betting on the "Vesper" clinical trials. These are for their obesity drug candidate, MET-097i. We’re expecting Phase 2b data in early 2026. If that data is good, the Pfizer stock price today per share might finally find a floor.

Analysts are split. The consensus is a "Hold." Out of about 30 analysts tracking it:

• Roughly 43% say "Buy" or "Strong Buy."
• Over 53% say "Hold."
• A tiny few are screaming "Sell."

The average price target is around $28.85. That’s a bit of upside from here, but nobody is expecting it to moon back to $50 or $60 anytime soon.

What Should You Actually Do?

Investing in Pfizer right now is a test of patience.
If you are a "yield pig" (and I say that with love) who just wants that quarterly check, the dividend looks safe for now. They have enough cash flow to cover it, even if things are tight.

However, if you're looking for "growth," you're probably looking in the wrong place. 2026 is going to be a transition year. It’s about cutting costs, integrating new acquisitions, and hoping a lab tech somewhere finds a breakthrough.

Actionable Takeaways for Investors

1. The Dividend Deadline: You must own the stock before January 23, 2026, to get the next $0.43 payout.
2. Watch the $25 Level: This has been a psychological floor. If it breaks significantly below $25, things could get ugly.
3. Wait for Clinical Data: Keep an eye out for any news regarding their GLP-1 (obesity) pipeline in February or March.
4. Reinvest or Not? If you believe in the 2029 turnaround, set your dividends to auto-reinvest (DRIP). If you’re nervous, take the cash and put it elsewhere.

Honestly, Pfizer is like a giant ship that’s currently turning. It takes a long time to change direction, and there might be some more splashing before it straightens out. Just don't expect a miracle overnight.

Check your brokerage app's "research" tab for the specific Metsera data release dates. Keep your eye on the adjusted EPS in the next quarterly report; if they beat that $2.80 low-end guidance, the market might finally give them some respect.